Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Nov;29(11):537-43.
doi: 10.1097/EJA.0b013e328356bad6.

No benefit from perioperative intravenous lidocaine in laparoscopic renal surgery: a randomised, placebo-controlled study

Affiliations
Randomized Controlled Trial

No benefit from perioperative intravenous lidocaine in laparoscopic renal surgery: a randomised, placebo-controlled study

Patrick Y Wuethrich et al. Eur J Anaesthesiol. 2012 Nov.

Abstract

Context: There is evidence that perioperative intravenous lidocaine administration can reduce analgesic requirement, improve recovery of bowel function and shorten the length of hospital stay. Its effect in laparoscopic renal surgery has not been investigated.

Objective: To evaluate the effect of systemic lidocaine on the length of hospital stay, readiness for discharge, opioid requirement, bowel function and inflammatory and stress response after laparoscopic renal surgery.

Design: Randomised, double-blind, placebo-controlled study.

Setting: Single tertiary centre where the study was carried out between July 2009 and February 2011.

Participants: Sixty-four patients completed the study. Inclusion criteria were laparoscopic renal surgery and American Society of Anesthesiologists physical status I to III. Exclusion criteria were steroid therapy, chronic opioid therapy, allergy to lidocaine, pre-existing bowel dysfunction and arrhythmia.

Intervention: Lidocaine was given as a 1.5 mg kg(-1) bolus during induction of anaesthesia, followed by an intraoperative infusion of 2 and 1.3 mg kg(-1) h(-1) for 24 h postoperatively. Primary outcome was the length of hospital stay. Secondary outcomes were readiness for discharge, opioid consumption, sedation, incidence of postoperative nausea and vomiting (PONV), return of bowel function and inflammatory and stress responses.

Main outcome measure: Length of hospital stay.

Results: The length of hospital stay did not differ between the groups [6 days for the lidocaine group, interquartile range (IQR) 5 to 7, range 2 to 8 vs. 5 days for the placebo group, IQR 5 to 6, range 2 to 11; P = 0.24). Lidocaine had no effect on readiness for discharge [4 days for the lidocaine group (IQR 5 to 7, range 2 to 8) vs. 4 days for the placebo group (IQR 5 to 7, range 2 to 11); P = 0.26], opioid consumption, postoperative sedation, PONV, return of bowel function and plasma concentrations of C-reactive protein, procalcitonin and cortisol.

Conclusion: Systemic perioperative lidocaine administration over 24 h did not influence the length of the hospital stay, readiness for discharge, opioid consumption, return of bowel function or inflammatory and stress responses after laparoscopic renal surgery.

Trial registration: ClinicalTrials.gov identifier NCT00789620.

PubMed Disclaimer

Publication types

MeSH terms

Associated data